Mutations in the Glucocerebrosidase Gene and Parkinson's Disease in Ashkenazi Jews
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A clinical association has been reported between type 1 Gaucher's disease, which is caused by a glucocerebrosidase deficiency owing to mutations in the glucocerebrosidase gene (GBA), and parkinsonism. We examined whether mutations in the GBA gene are relevant to idiopathic Parkinson's disease. METHODS: A clinic-based case series of 99 Ashkenazi patients with idiopathic Parkinson's disease, 74 Ashkenazi patients with Alzheimer's disease, and 1543 healthy Ashkenazi Jews who underwent testing to identify heterozygosity for certain recessive diseases were screened for the six GBA mutations (N370S, L444P, 84GG, IVS+1, V394L, and R496H) that are most common among Ashkenazi Jews. RESULTS: Thirty-one patients with Parkinson's disease (31.3 percent; 95 percent confidence interval, 22.2 to 40.4 percent) had one or two mutant GBA alleles: 23 were heterozygous for N370S, 4 were heterozygous for 84GG, 3 were homozygous for N370S, and 1 was heterozygous for R496H. Among the 74 patients with Alzheimer's disease, 3 were identified as carriers of Gaucher's disease (4.1 percent; 95 percent confidence interval, 0.0 to 8.5 percent): 2 were heterozygous for N370S, and 1 was heterozygous for 84GG. Ninety-five carriers of Gaucher's disease were identified among the 1543 control subjects (6.2 percent; 95 percent confidence interval, 5.0 to 7.4 percent): 92 were heterozygous for N370S, and 3 were heterozygous for 84GG. Patients with Parkinson's disease had significantly greater odds of being carriers of Gaucher's disease than did patients with Alzheimer's disease (odds ratio, 10.8; 95 percent confidence interval, 3.0 to 46.6; P<0.001) or control subjects (odds ratio, 7.0; 95 percent confidence interval, 4.2 to 11.4; P<0.001). Among the patients with Parkinson's disease, patients who were carriers of Gaucher's disease were younger than those who were not carriers (mean [+/-SD] age at onset, 60.0+/-14.2 years vs. 64.2+/-11.7 years; P=0.04). CONCLUSIONS: Our results suggest that heterozygosity for a GBA mutation may predispose Ashkenazi Jews to Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“It is a center for cellular signaling and signal integration, has responsibilities in trafficking cargo, and functionally interacts with other organelles.1,9”
From The lysosome and proteostatic stress at the intersection of pediatric neurological disorders and adult neurodegenerative diseases (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredIn the citing paper
“there is an increased frequency of mutations in the gene encoding GBA among patients with Parkinson’s disease (e.g. Aharon-Peretz et al. 2004; Clark et al. 2007; Gan-Or et al. 2008; Lwin et al. 2004), and vice versa (Sidransky et al. 2009).”
From Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson’s, Huntington’s, Alzheimer’s, prions, bactericides, chemical toxicology and others as examples (2010) · cites this paper as Aharon-Peretz et al. 2004
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
Williams, J. B. W., & First, M. (2013) · Encyclopedia of Social Work · doi:10.1093/acrefore/9780199975839.013.104 · Cited by 109,519
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Dauer, W., & Przedborski, S. (2003) · Neuron · doi:10.1016/s0896-6273(03)00568-3 · Cited by 5,469
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Unified Parkinson's Disease Rating Scale
(2012) · SpringerReference · doi:10.1007/springerreference_184495 · Cited by 3,066
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Impairment of the Ubiquitin-Proteasome System by Protein Aggregation
Bence, N. F., Sampat, R. M., & Kopito, R. R. (2001) · Science · doi:10.1126/science.292.5521.1552 · Cited by 2,187
Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale
Fahn, S. (1987) · Medical Entomology and Zoology · Cited by 2,163
Research works printed but not linked: 1
- 10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j · doi:10.1002/(sici)1098-1004(1998)12:4<240::aid-humu4>3.0.co;2-j
Cited by
Items 301–400 of 608
Factors Influencing the Measurement of Lysosomal Enzymes Activity in Human Cerebrospinal Fluid
Persichetti, E., Chiasserini, D., Parnetti, L., Eusebi, P., Paciotti, S., Carlo, C. D., Codini, M., Tambasco, N., Rossi, A., El‐Agnaf, O. M. A., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0101453 · Cited by 29
“Several reports have demonstrated that GBA1 mutations are an important risk factor for PD (7, 8, 9, 10).”
BackgroundGenomic aspects of sporadic neurodegenerative diseases
Mitsui, J., & Tsuji, S. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.098 · Cited by 31
Greiner-Tollersrud, O. K., & Berg, T. (2007) · Springer eBooks · doi:10.1007/0-387-28957-7_6 · Cited by 28
Conversion of Quinazoline Modulators from Inhibitors to Activators of β-Glucocerebrosidase
Zheng, J., Jeon, S., Jiang, W., Burbulla, L. F., Ysselstein, D., Oevel, K., Krainc, D., & Silverman, R. B. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01294 · Cited by 28
What lysosomes actually tell us about Parkinson’s disease?
Bourdenx, M., & Dehay, B. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.02.008 · Cited by 26
Zheng, W., & Fan, D. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.851135 · Cited by 28
“3% in the Ashkenazi Jewish population with PD (Aharon-Peretz et al., 2004; Clark et al., 2005) but ranged from 2.”
BackgroundAltered transcriptome-proteome coupling indicates aberrant proteostasis in Parkinson’s disease
Dick, F., Tysnes, O., Alves, G. W., Nido, G. S., & Tzoulis, C. (2023) · iScience · doi:10.1016/j.isci.2023.105925 · Cited by 26
“This is further supported 20 by the fact that mutations in GBA, encoding the lysosomal enzyme glucocerebrosidase, greatly 21 increase the risk of PD [1].”
BackgroundThe genetic basis of multiple system atrophy
Tseng, F. S., Foo, J. Q. X., Mai, A. S., & Tan, E. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-03905-1 · Cited by 29
Genetic Convergence of Parkinson’s Disease and Lysosomal Storage Disorders
Deng, H., Xiu, X., & Jankovic, J. J. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8832-4 · Cited by 32
Jamrozik, Z., Ługowska, A., Sławek, J. W., & Kwieciński, H. (2009) · Journal of Neurology · doi:10.1007/s00415-009-5363-4 · Cited by 26
Dung, V. M., & Thảo, Đ. T. P. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-0529-0_4 · Cited by 28
Glucocerebrosidase mutations are not a common risk factor for Parkinson disease in North Africa
Nishioka, K., Vilariño‐Güell, C., Cobb, S. A., Kachergus, J. M., Ross, O. A., Wider, C. W., Gibson, R. A., Hentati, F., & Farrer, M. J. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.066 · Cited by 27
“3%) among Ashkenazi Jewish PD patients [1].”
BackgroundYılmaz, A., Ashrafi, N., Ashrafi, R., Akyol, S., Saiyed, N., Kerševičiūtė, I., Gabrielaitė, M., Gordevičius, J., & Graham, S. F. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01023-x · Cited by 30
Gan‐Or, Z., Bar‐Shira, A., Gurevich, T., Giladi, N., & Orr‐Urtreger, A. (2011) · Neurogenetics · doi:10.1007/s10048-011-0293-6 · Cited by 26
Coding variation in GBA explains the majority of the SYT11‐GBA Parkinson's disease GWAS locus
Blauwendraat, C., Brás, J., Nalls, M. A., Lewis, P. A., Hernandez, D. G., & Singleton, A. (2018) · Movement Disorders · doi:10.1002/mds.103 · Cited by 25
“A landmark discovery in the genetics of Parkinson’s disease (PD) was the determination that mutations in the gene encoding glucocerebrosidase (GBA) convey risk for PD and dementia with Lewy bodies.(1,2) Mutations in GBA are also causing the autosomal-recessive disorder Gaucher’s disease (GD).”
BackgroundOrtega, R. A., Bressman, S., Raymond, D., Ozelius, L. J., Katsnelson, V., Leaver, K. R., Swan, M. C., Shanker, V., Miravite, J., Wang, C., et al. (2022) · Movement Disorders · doi:10.1002/mds.29197 · Cited by 26
From rare to common and back again: 60years of lysosomal dysfunction
Coutinho, M. F., & Alves, S. (2015) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2015.08.008 · Cited by 30
Gaucher disease: a lysosomal neurodegenerative disorder.
Huang, W., Zhang, X., & Chen, W. W. (2015) · PubMed · Cited by 25
Clinical profiles associated with LRRK2 and GBA mutations in Brazilians with Parkinson's disease
da Silva, C. P., Abreu, G. D. M., Cabello, P. H., Campos, M., Pereira, J. S., Ramos, S. R. D. A., Nascimento, C. M., Voigt, D. D., de Rosso, A. L. Z., Leite, M. A. A., et al. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3249 · Cited by 27
“Heterozygous mutations in the GBA gene are also significant risk factors for PD [9,10], and the two most common mutations, L444P and N370S, account for 70% of all GBA mutant alleles in PD patients [11].”
Octarepeat changes of prion protein in Parkinson's disease
Wang, V., Chuang, T., Soong, B., Shan, D., & Kao, M. (2008) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.03.003 · Cited by 25
“Suspicious genes have been evaluated in patients with sporadic PD, for example, the beta-glucocerebrosidase [2].”
BackgroundThe Progress of Induced Pluripotent Stem Cells as Models of Parkinson’s Disease
Kang, J.-F., Tang, B., & Guo, J. (2016) · Stem Cells International · doi:10.1155/2016/4126214 · Cited by 24
Deep phenotyping for precision medicine in Parkinson's disease
Schalkamp, A., Rahman, N., Monzón‐Sandoval, J., & Sandor, C. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049376 · Cited by 27
“However, both heterozygous and homozygous N370S mutations in GBA have been found among PD patients with no GD symptoms (Aharon-Peretz et al., 2004).”
BackgroundSassi, C. (2011) · InTech eBooks · doi:10.5772/20390 · Cited by 26
Chen, J., Li, W., Zhang, T., Wang, Y., Jiang, X., & Xu, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0115747 · Cited by 24
“Mutations of glucocerebrosidase (GBA) gene which located at chromosome 1q21 and encoding the enzyme glucocerebrosidase [3], have been significantly associated with PD susceptibility in Ashkenazi Jewish patients [4].”
BackgroundParkinson's Disease: From Genetics to Clinical Practice
Clarimón, J., & Kulisevsky, J. (2014) · Current Genomics · doi:10.2174/1389202914666131210212305 · Cited by 27
“Since the first discovery that resulted from the analysis of Ashkenazi Jewish patients, [48] many studies worldwide have replicated this finding [49-54].”
BackgroundOrenstein, M., Barbouth, D., Bodamer, O. A., & Weinreb, N. J. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-9-45 · Cited by 24
“Of more than 350 GBA1 variant alleles that are associated with GD, 6 mutations account for 98% of those found in the Ashkenazi Jewish population in which GD1 is especially prevalent [7].”
Backgrounddos Santos, A. V., Pestana, C. P., Diniz, K. R. D. S., Campos, M., Abdalla, C. B., de Rosso, A. L. Z., Pereira, J. S., Nicaretta, D. H., de Carvalho, W. L., dos Santos, J. M., et al. (2010) · Neuroscience Letters · doi:10.1016/j.neulet.2010.08.083 · Cited by 26
Gaucher and Parkinson diseases: Unexpectedly related
Rogaeva, E. A., & Hardy, J. (2008) · Neurology · doi:10.1212/01.wnl.0000314657.92762.0f · Cited by 24
Dynamic Allostery: Evolution's Double-Edged Sword in Protein Function and Disease
Campitelli, P., Kazan, I. C., Hamilton, S., & Ozkan, S. B. (2025) · Journal of Molecular Biology · doi:10.1016/j.jmb.2025.169175 · Cited by 26
Lerche, S., Schulte, C., Srulijes, K., Pilotto, A., Rattay, T. W., Hauser, A., Stransky, E., Deuschle, C., Csóti, I., Lachmann, I., et al. (2017) · Movement Disorders · doi:10.1002/mds.27199 · Cited by 23
Rethinking fatigue in Gaucher disease
Zion, Y. C., Pappadopulos, E. A., Wajnrajch, M. P., & Rosenbaum, H. (2016) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-016-0435-x · Cited by 28
“Pulmonary hypertension, cholelithiasis, and autoimmune phenomena may occur in Gaucher patients and the mutations for Type 1 GD might predispose carriers and patients with GD to Parkinson disease [2, 6, 7].”
BackgroundSelf-citationManickam, M., Ravanan, P., Singh, P., & Talwar, P. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00148 · Cited by 25
Precision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy
Straccia, G., Colucci, F., Eleopra, R., & Cilia, R. (2022) · Brain Sciences · doi:10.3390/brainsci12101308 · Cited by 23
“Nonetheless, despite similar UPDRS III scores among GBA carriers and non-carriers [189,191,292,293], the H&Y stage and Levodopa-non responsive symptoms are significantly higher in GBA carriers compared to PD noncarriers [189,191], postural instability/gait phenotype (PIGD) is more frequent in GBA-PD [189,191], and the…”
BackgroundMenozzi, E., Schapira, A. H. V., Blandini, F., & Avenali, M. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01259-1 · Cited by 22
Ren, J., Zhan, X., Zhou, H., Guo, Z., Xing, Y., Yin, H., Xue, C., Wu, J., & Liu, W. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14387 · Cited by 26
“3,4 8– 12 Interestingly, the onset age also significantly affects the clinical phenotype and disease progression of PD. 13– 15 Early-onset iPD (early-iPD) patients generally possess a lower cognitive deficit risk, a higher levodopa-associated dyskinesia prevalence, and slower disease progression.”
BackgroundThe L444P GBA mutation is associated with early‐onset Parkinson's disease in Mexican Mestizos
Rincón, M. D. L. G., Monroy‐Jaramillo, N., Martínez, A. S., Gómez, P. Y., Boll, M., López, M., & Vilatela, M. A. (2013) · Clinical Genetics · doi:10.1111/cge.12084 · Cited by 26
Parkinson's Disease: From Genetics to Treatments
Fan, H., Chen, S., Harn, H., & Lin, S. (2013) · Cell Transplantation · doi:10.3727/096368912x655082 · Cited by 26
Design and Synthesis of Potent Quinazolines as Selective β-Glucocerebrosidase Modulators
Zheng, J., Chen, L., Schwake, M., Silverman, R. B., & Krainc, D. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00930 · Cited by 22
The Birth of the Modern Era of Parkinson’s Disease Genetics
Singleton, A., Hardy, J., & Gasser, T. (2017) · Journal of Parkinson s Disease · doi:10.3233/jpd-179009 · Cited by 22
“This observation was made through the keen clinical observation that the parents and grandparents of children with Gaucher’s disease had an increased incidence of PD (odds ration of ∼4) [16, 17].”
BackgroundYeboah, F., Kim, T., Bill, A., & Dettmer, U. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104543 · Cited by 22
GBA1 mutations: Prospects for exosomal biomarkers in α-synuclein pathologies
Johnson, P. H., Weinreb, N. J., Cloyd, J. C., Tuite, P., & Kartha, R. V. (2019) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2019.10.006 · Cited by 23
“It was then discovered that GBA1 mutations were also common in PD patients without GD [20, 21].”
BackgroundSystematic Genetic Analysis of the SMPD1 Gene in Chinese Patients with Parkinson’s Disease
Deng, S., Deng, X., Song, Z. J., Xiu, X., Guo, Y., Xiao, J., & Deng, H. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9426-5 · Cited by 21
Lipid Classes and Fatty Acid Patterns are Altered in the Brain of γ‐Synuclein Null Mutant Mice
Guschina, I. A., Millership, S. J., O’Donnell, V. B., Ninkina, N. N., Harwood, J. L., & Buchman, V. L. (2010) · Lipids · doi:10.1007/s11745-010-3486-0 · Cited by 21
Parkinsonism in Type I Gaucher's Disease
Itokawa, K., Tamura, N., Kawai, N., Shimazu, K., & Ishii, K. (2006) · Internal Medicine · doi:10.2169/internalmedicine.45.1790 · Cited by 21
“Aharon-Peretz et al (2) reported that 31.”
BackgroundInfluentialTrio approach reveals higher risk of PD in carriers of severe vs. mild GBA mutations
Arkadir, D., Dinur, T., Mullin, S., Mehta, A. B., Baris, H. N., Alcalay, R. N., & Zimran, A. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.11.007 · Cited by 21
Sheth, J. J., Pancholi, D., Mistri, M. A., Nath, P., Ankleshwaria, C., Bhavsar, R., Puri, R. D., Phadke, S. R., & Sheth, F. J. (2018) · BMC Medical Genetics · doi:10.1186/s12881-018-0687-5 · Cited by 21
ITCH regulates degradation of mutant glucocerebrosidase: implications to Gaucher disease
Maor, G., Filocamo, M., & Horowitz, M. (2012) · Human Molecular Genetics · doi:10.1093/hmg/dds535 · Cited by 22
Parkinson's Disease: Genetics and Pathogenesis
Testa, C. M. (2007) · Wiley eBooks · doi:10.1002/9780470101001.hcn063 · Cited by 21
Progranulinopathy: A diverse realm of disorders linked to progranulin imbalances
Huang, G., Jian, J., & Liu, C.-J. (2023) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2023.11.001 · Cited by 24
Identifying PD-causing genes and genetic susceptibility factors
Gasser, T. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)83001-8 · Cited by 28
Giraldo, P., Capablo, J. L., Alfonso, P., Garcia‐Rodriguez, B., Latre, P., Irún, P., de Cabezón, A. S., & Pocoví, M. (2011) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9298-4 · Cited by 20
“2009), reports of case-control studies performed in the Ashkenazi and other populations showed a higher prevalence of GBA mutations in patients with PD compared to the general population (Aharon-Peretz et al. 2004; Ziegler et al. 2007; Clark et al. 2007; Kalinderi et al. 2009; Sidransky et al. 2009).”
ResultIshay, Y., Zimran, A., Szer, J., Dinur, T., Ilan, Y., & Arkadir, D. (2016) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2016.10.028 · Cited by 20
Candidate Molecules for Chemical Chaperone Therapy of G M1 -Gangliosidosis
Higaki, K., Ninomiya, H., Suzuki, Y., & Nanba, E. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.123 · Cited by 21
Kumar, M., Srikanth, M. P., Deleidi, M., Hallett, P. J., Isacson, O., & Feldman, R. A. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad025 · Cited by 20
Sun, Y., Zhou, X., Liang, X., Lin, J., Xu, Y., Chen, C., Wei, S., Chen, Q.-S., Liu, F., Zhao, J., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00518-9 · Cited by 20
GBA1 in Parkinson’s disease: variant detection and pathogenicity scoring matters
Gabbert, C., Schaake, S., Lüth, T., Much, C., Klein, C., Aasly, J. O., Farrer, M. J., & Trinh, J. (2023) · BMC Genomics · doi:10.1186/s12864-023-09417-y · Cited by 20
“, 2004 (80) (15525722) 99/1543 Ashkenazi Jewish Variant screening N370S, L444P,”
Hu, X., Song, L.-Z.-X., Zhang, Z.-Z., Ruan, X., Li, H., Yu, Z., & Huang, L. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1358525 · Cited by 22
Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
Almeida, M. R. (2012) · Frontiers in Neurology · doi:10.3389/fneur.2012.00065 · Cited by 19
“Once more, patients who were carriers of GBA mutations were younger than those who were not carriers (Aharon-Peretz et al., 2004).”
BackgroundStaropoli, J. F., Xin, W. W., Barone, R., Cotman, S. L., & Sims, K. B. (2012) · BMC Medical Genetics · doi:10.1186/1471-2350-13-50 · Cited by 20
“Interestingly, genetic defects in lysosomal storage, such as variants of glucocerebrosidase associated with Gaucher disease [26], and defects in mitochondrial DNA synthesis, including mutations in POLG1 [27,28], independently contribute to forms of parkinsonism, suggesting that impairments in lysosomal and”
BackgroundGaucher disease and the synucleinopathies: refining the relationship
Campbell, T. N., & Choy, F. Y. M. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-12 · Cited by 20
“faced reporting an increased frequency of GBA mutations in different cohorts with parkinsonism [25-30].”
BackgroundParkinsonism in Inherited Metabolic Disorders: Key Considerations and Major Features
Limphaibool, N., Iwanowski, P. S., Holstad, M. J. V., & Perkowska, K. (2018) · Frontiers in Neurology · doi:10.3389/fneur.2018.00857 · Cited by 21
“significant risk factor for PD development is of significant interest (10, 80, 81).”
BackgroundCherin, P., Sedel, F., Mignot, C., Schüpbach, M. W. M., Gourfinkel‐An, I., Verny, M., & Baumann, N. (2006) · Revue Neurologique · doi:10.1016/s0035-3787(06)75120-7 · Cited by 20
Parkinson disease is a fatty acidopathy
Fanning, S., & Selkoe, D. J. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01142-2 · Cited by 20
Galper, J., Mori, G., McDonald, G., Rastegar, D. A., Pickford, R., Lewis, S. J. G., Halliday, G. M., Kim, W. S., & Dzamko, N. L. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00741-y · Cited by 22
Transcranial sonography in patients with Parkinson's disease with glucocerebrosidase mutations
Kresojević, N. D., Mijajlovic, M. D., Perić, S., Pavlovic, A. M., Svetel, M. V., Janković, M. Z., Dobričić, V. S., Novaković, I. V., Lakočević, M. B., Klein, C., et al. (2013) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2012.12.006 · Cited by 18
Traversing a wormhole to combat Parkinson’s disease
Caldwell, G. A., & Caldwell, K. A. (2008) · Disease Models & Mechanisms · doi:10.1242/dmm.000257 · Cited by 19
Mutations in GBA and risk of Parkinson’s disease: a meta-analysis based on 25 case-control studies
Mao, X., Wang, T., Peng, R., Chang, X., Li, N., Gu, Y., Zhao, D., Liao, Q., & Liu, M. (2013) · Neurological Research · doi:10.1179/1743132813y.0000000224 · Cited by 18
Lysosomal defects in ATP13A2 and GBA associated familial Parkinson’s disease
Sato, S., Li, Y., & Hattori, N. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1779-7 · Cited by 18
“A subsequent meta-analysis detected rare variants of GBA as risk factors of sporadic PD (Aharon-Peretz et al. 2004; Sidransky et al. 2009).”
BackgroundSTING-mediated neuroinflammation: a therapeutic target in neurodegenerative diseases
Zhang, H., He, Z., Yin, C., Yang, S., Li, J., Lin, H. R., Hu, G., Wu, A., Qin, D., Yu, L., et al. (2025) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2025.1659216 · Cited by 20
Lipids and α-Synuclein: adding further variables to the equation
Schepers, J., Löser, T., & Behl, C. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1455817 · Cited by 17
Recent advances in the genetics of dementia with Lewy bodies
Bonifati, V. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0030-1 · Cited by 16
“An association between GBA missense mutations and PD was found, particularly among Ashkenazi Jews [ 26 ,27].”
BackgroundPathological Mechanisms and Clinical Aspects of GBA1 Mutation-Associated Parkinson’s Disease
Stoker, T. B., Torsney, K., & Barker, R. A. (2018) · Codon Publications eBooks · doi:10.15586/codonpublications.parkinsonsdisease.2018.ch3 · Cited by 25
GBA1 and The Immune System: A Potential Role in Parkinson’s Disease?
Al‐Azzawi, Z. A. M., Arfaie, S., & Gan‐Or, Z. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223423 · Cited by 21
The Genetics of Alzheimer’s Disease and Parkinson’s Disease
Bekris, L. M., Yu, C., Bird, T. D., & Tsuang, D. W. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_21 · Cited by 19
“3% (Aharon-Peretz et al., 2004).”
BackgroundThe emergence of Parkinson disease among patients with Gaucher disease
Elstein, D., Alcalay, R. N., & Zimran, A. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.007 · Cited by 16
Induced Pluripotent Stem Cell Modeling of Gaucher’s Disease: What Have We Learned?
Santos, D., & Tiscórnia, G. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040888 · Cited by 17
Eblan, M. J., Scholz, S. W., Stubblefield, B. K., Gutti, U., Göker-Alpan, Ö., Hruska, K. S., Singleton, A., & Sidransky, E. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.05.032 · Cited by 17
Vidyadhara, D. J., Bäckström, D. C., Chakraborty, R., Ruan, J., Park, J.-M., Mistry, P. K., & Chandra, S. S. (2025) · Nature Communications · doi:10.1038/s41467-025-63444-9 · Cited by 17
Maszlag-Török, R., Zádori, D., Török, N., Csility, É., Vécsei, L., & Klivènyi, P. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.11.001 · Cited by 16
“Three previously described primer pairs were used separately to amplify the DNA region of each mutation [1, 39].”
Multiple myeloma and Gaucher genes
Rosenbloom, B. E., Becker, P. S., & Weinreb, N. J. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e318195e2b6 · Cited by 15
Glucocerebrosidase, a new player changing the old rules in Lewy body diseases
Yang, N.-Y., Lee, Y.-N., Lee, H.-J., Kim, Y. S., & Lee, S. (2013) · Biological Chemistry · doi:10.1515/hsz-2012-0322 · Cited by 20
Lipid disequilibrium in biological membranes, a possible pathway to neurodegeneration
Witt, S. N. (2014) · Communicative & Integrative Biology · doi:10.4161/19420889.2014.993266 · Cited by 15
Zhang, X. (2012) · The Chinese Journal of Physiology · doi:10.4077/cjp.2012.baa076 · Cited by 17
Collins, L., Williams‐Gray, C. H., Morris, E., Deegan, P. B., Cox, T. M., & Barker, R. A. (2018) · Journal of Neurology · doi:10.1007/s00415-018-8908-6 · Cited by 15
Arkadir, D., Dinur, T., Becker‐Cohen, M., Revel‐Vilk, S., Tiomkin, M., Brüggemann, N., Cozma, C., Rolfs, A., & Zimran, A. (2019) · European Journal of Neurology · doi:10.1111/ene.13927 · Cited by 15
“Parkinson’s disease is more common in both GBA single mutation carriers [1,2] and in patients with GD [3].”
BackgroundZhang, L., Okada, T., Badawy, S. M. M., Hirai, C., Kajimoto, T., & Nakamura, S. (2017) · Scientific Reports · doi:10.1038/srep44248 · Cited by 16
Gaucher disease with jawbone involvement: a case report
Ahmadieh, A., Farnad, F., & Sedghizadeh, P. P. (2014) · Journal of Medical Case Reports · doi:10.1186/1752-1947-8-360 · Cited by 15
“The disease is caused by a defect in the housekeeping gene lysosomal glucocerebrosidase on the first chromosome (1q22) [1].”
BackgroundRapid screening of ATP13A2 variant with high‐resolution melting analysis
Funayama, M., Tomiyama, H., Wu, R., Ogaki, K., Yoshino, H., Mizuno, Y., & Hattori, N. (2010) · Movement Disorders · doi:10.1002/mds.23106 · Cited by 15
Parkinsonism in type 1 Gaucher's disease
Spitz, M. (2006) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2005.076240 · Cited by 15
Prodromal Cognitive Deficits and the Risk of Subsequent Parkinson’s Disease
Speelberg, H. B., Daalen, J. M. J., Bloem, B. R., Gagnon, J., Post, B., & Darweesh, S. K. L. (2022) · Brain Sciences · doi:10.3390/brainsci12020199 · Cited by 14
“In addition, genetic risk factors (such as LRRK2 and GBA, for example) have been established and may aid in identifying individuals in their prodromal phase [9,10].”
BackgroundKim, J. J., Daadi, E. W., Oh, T. T., Daadi, E. S., & Daadi, M. M. (2022) · Genes · doi:10.3390/genes13111937 · Cited by 14
“Mutations in this gene result in the accumulation of glycolipid substrates in lysosomes which disrupts lysosomal function and can lead to an autosomal recessive lysosomal storage disorder known as Gaucher’s disease (GD) [289].”
BackgroundMDPD: an integrated genetic information resource for Parkinson's disease
Tang, S., Zhang, Z. H., Kavitha, G., Tan, E., & Ng, S. K. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn770 · Cited by 15
Genetic analysis of lysosomal alpha-galactosidase A gene in sporadic Parkinson's disease
Wu, G., Pang, S., Feng, X., Zhang, A., Li, J., Gu, K., Huang, J. A., Dong, H., & Yan, B. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.05.238 · Cited by 15
From Genes to Proteins in Mendelian Parkinson's Disease: An Overview
Cetinkaya, C. P., Lesage, S., Brice, A., & Başak, A. N. (2009) · The Anatomical Record · doi:10.1002/ar.20968 · Cited by 15
“Indeed, a-synuclein is known to be degraded by lysosomes and a lysosomal enzyme, glucocerebrosidase, is linked to Lewy body disorders (Lwin et al., 2004; Aharon-Peretz et al., 2004; Cuervo et al., 2004; Lee et al., 2004; Goker-Alpan et al., 2006).”
BackgroundGBA ‐associated parkinsonism and dementia: beyond α‐synucleinopathies?
Pilotto, A., Schulte, C., Hauser, A., Biskup, S., Munz, M., Brockmann, K., Schaeffer, E., Synofzik, M., Maetzler, W., Suenkel, U., et al. (2015) · European Journal of Neurology · doi:10.1111/ene.12894 · Cited by 15
Jellinger, K. A. (2011) · Wiley eBooks · doi:10.1002/9781444341256.ch21 · Cited by 15
Hughes, D. A., Ginsberg, L., Baker, R., Goodwin, S., Milligan, A., Richfield, L., & Mehta, A. B. (2006) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2006.07.010 · Cited by 14
“In a recently reported study of Ashkenazi patients [3], the frequency of a N370S glucocerebrosidase gene mutation in patients with Parkinson’s disease and GD was five times that among healthy control subjects, and three out of the case series of 99 patients were homozygous for this mutant allele.”
BackgroundMitsui, J., Fukuda, Y., Azuma, K., Tozaki, H., Ishiura, H., Takahashi, Y., Goto, J., & Tsuji, S. (2010) · Journal of Human Genetics · doi:10.1038/jhg.2010.46 · Cited by 13
Amaral, C. E. D. M., Lopes, P. F., Ferreira, J. C. C., Alves, E. A. C., Montenegro, M. V. B., da Costa, E. T., Yamada, E. S., Cavalcante, F. O. Q., & da Silva, L. C. S. (2019) · Arquivos de Neuro-Psiquiatria · doi:10.1590/0004-282x20190006 · Cited by 14
Diseases of movement and system degenerations
Ince, P. G., Clark, B., Holton, J. L., Révész, T., & Wharton, S. B. (2008) · CRC Press eBooks · doi:10.1201/b13319-14 · Cited by 34
Metadata
- Authors
- Aharon-Peretz, J., Rosenbaum, H., & Gershoni-Baruch, R.
- Affiliations
- Technion – Israel Institute of Technology (IL)
- ORCID
- Rosenbaum, Hanna
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-11-04
- Volume
- 351
- Issue
- 19
- Pages
- 1972-1977
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1992253341
- Cited by
- 597
- References
- 32
- Citations by year
- 2026: 14 · 2025: 20 · 2024: 17 · 2023: 21 · 2022: 32 · 2021: 27 · 2020: 16 · 2019: 25 · 2018: 26 · 2017: 32 · 2016: 35 · 2015: 29 · 2014: 28 · 2013: 39 · 2012: 28
- FWCI
- 14.61
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Glycogen Storage Diseases and Myoclonus
- Keywords
- Parkinson's disease, glucocerebrosidase gene, GBA mutations, Ashkenazi Jews, N370S mutation, Alzheimer's disease, parkinsonism, genetic screening, heterozygosity, genotype-phenotype correlation, gene-environment interaction
- MeSH terms
- Alzheimer Disease, DNA Mutational Analysis, Female, Glucosylceramidase, Heterozygote, Humans, Jews, Male, Mutation, Parkinson Disease, Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.